^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IFIT1 overexpression

i
Other names: IFIT1, Interferon Induced Protein With Tetratricopeptide Repeats 1, Interferon-Induced Protein With Tetratricopeptide Repeats 1, Interferon-Induced 56 KDa Protein, IFI-56K, IFIT-1, IFNAI1, G10P1, IFI56, ISG56, P56, Interferon, Alpha-Inducible Protein (MW 56kD), Interferon-Inducible MRNA 561, GARG-16, IFI-56, RNM561, IFIT1, C56
Entrez ID:
1year
MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase-signal transducer and activator of transcription pathway. (PubMed, Endocr J)
Furthermore, silencing IFIT1 via an siRNA elicited an inflammatory response, whereas IFIT1 overexpression ameliorated hepatic inflammation and fibrosis in a manner comparable to that induced by IFN-α treatment. Taken together, our findings suggest that miR-122 and its target, IFIT1, reciprocally regulate the inflammatory response associated with IFN through the Jak/STAT pathway.
Journal
|
IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFNA1 (Interferon Alpha 1) • MIR122 (MicroRNA 122)
|
IFIT1 overexpression
over1year
Interferon-Induced Transmembrane Protein 1 (IFITM1) Is Downregulated in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. (PubMed, Int J Mol Sci)
In xenograft mice injected with MPNST cells, IFN-γ treatment successfully suppressed tumor progression with increased IFITM1 expression and decreased Ras and ERK1/2 activation in tumor tissues. Collectively, these results suggest that IFITM1 is closely involved in MPNST pathogenesis and that IFN-γ is a good candidate for the therapeutic treatment of MPNSTs in NF1.
Journal
|
NF1 (Neurofibromin 1) • IFNG (Interferon, gamma) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK3 (Mitogen-Activated Protein Kinase 3)
|
NF1 mutation • IFNG expression • IFIT1 overexpression • NF1 overexpression
2years
Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3. (PubMed, Cancer Sci)
The antitumor effect of gefitinib on orthotopic TW2.6/LOXL2 xenograft tumor was fourfold higher than that on controls. Our results indicate that LOXL2 expression is a strong prognostic factor for OSCC and may be used as a marker to identify patients most likely to respond to EGFR-targeted therapy.
Journal
|
IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • LOXL2 (Lysyl Oxidase Like 2)
|
IFIT1 overexpression • IFIT3 overexpression
|
gefitinib
over3years
circIFITM1/miR-802/Foxp1 Axis Participates in Proliferation and Invasion of Lovo Cells. (PubMed, Dis Markers)
The cyclicity of circIFITM1 was confirmed by agarose gel electrophoresis and Sanger sequencing, and the stability of circIFITM1 was confirmed by actinomycin D assay...The overexpression of circIFITM1 downregulated miR-802 and upregulated FOXP1. circIFITM1 facilitates the proliferative and invasive abilities via miR-802/FOXP1 in Lovo cells.
Journal
|
FOXP1 (Forkhead Box P1)
|
IFIT1 overexpression • FOXP1 overexpression
|
dactinomycin
almost4years
The Highly Expressed IFIT1 in Nasopharyngeal Carcinoma Enhances Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells. (PubMed, Mol Biotechnol)
In conclusion, a total of 49 DEGs and 11 hub genes in NPC using the integrated bioinformatics analysis. IFIT1 was up-regulated in the NPC cells lines, and IFIT1 may act as an oncogene by promoting NPC cell proliferation, migration, and invasion.
Journal
|
CXCL11 (C-X-C Motif Chemokine Ligand 11) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • COL22A1 (Collagen Type XXII Alpha 1 Chain) • COL5A1 (Collagen Type V Alpha 1 Chain)
|
IFIT1 overexpression
over4years
Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. (PubMed, Cancer Lett)
Notably, siRNA knockdown of p65 reduces IFITM1 expression and a drug-repurposing screen of FDA approved compounds identified parthenolide, an NFκB inhibitor, as a cytotoxic agent for TNBC and an inhibitor of IFITM1 in vitro and in vivo. Overall, our findings suggest that targeting IFITM1 by suppressing interferon-alpha/NFκB signaling represents a novel therapeutic strategy for TNBC treatment.
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • RELA (RELA Proto-Oncogene)
|
IFIT1 overexpression